大华继显发表研究报告指，中国生物技术行业已进入加速增长阶段，各企业正扩展其创新商业产品组合，达成重要的对外许可授权交易，且获得超预期的盈利能力。持续的政策支持和全球化努力将进一步推动该行业扩张，该行相信该行业将继续表现出色，有望在未来几年实现可持续成长，对该行业的评级上调至“增持”。该行强调，信达生物、翰森制药和中国生物制药为该行首选。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.